Home > What we are looking for > Commercial stage products

The aim is to expand the business in synergistic therapeutics areas, to enlarge product portfolio and to increase critical mass in the geopgraphies where Chiesi branches already exist.

Europe

In EU Chiesi is focused on expanding business in synergistic therapeutics and development areas Affiliates business opportunities:

Assets acquisition or In-licensing in-market products in the field of Respiratory, Special Care (including Orphan Drugs),
Asset acquisition or In-licensing in-market products in the field of Consumer Healthcare (OTC / OTX),
Chiesi branches already exist

Total Staff: ~ 3,800

Commercial Staff : ~ 1,600

Turnover : ~€ 1,100 M

Focus: respiratory, neonatology, transplantology, and rare diseases

In the US, Chiesi is looking for products in the hospital space and in rare diseases. Within the hospital space, the interest lies primarily in acute cardiovascular, hematology, allergy/immunology and nephrology.

Total Staff: ~250

Commercial Staff : ~ 130

Turnover: ~ € 300 M

Focus: hospital setting products (neonatology, acute cardiovascular care and cystic fibrosis)

Emerging Markets

In emerging countries Chiesi is focused on expanding business in synergistic therapeutic areas and to develop Affiliates business opportunities:

Assets acquisition or in-licensing in-market products in the field of Respiratory, Special Care (including Orphan Drugs)
Company acquisition to increase critical mass in the geography where Chiesi branches already exist (Brazil, China, Mexico, Pakistan, Russia, CIS, Turkey)

Total Staff: ~1200

Commercial Staff: ~800

Turnover: ~€ 300 M

Focus: respiratory, neonatology, and hospital setting products

VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

CHIESI ON THE WEB